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Abstract
 .A growing number of amphiphiles are known to form high axial ratio microstructures HARMs such as the hollow
cylindrical microstructures called lipid tubules. As a prelude to exploring the potential of HARMs formed from lipopeptides
in controlled release drug delivery, several microstructure formation conditions were investigated. We report the preparation
 .of several glutamic acid dialkyl amides with varying alkyl chain lengths bearing a variety of peptides 1–4 amino acids
w  . xpeptide-Glu- NHC H , ns12, 14, 16 . These surfactants have been rapidly and efficiently converted into HARMsn 2 nq1 2
in aqueous buffer at physiological pH and ionic strength, or in buffer containing MeOH or EtOH. Helical ribbons and
tubular HARMs were produced that were stable for as long as 6 months below the phase transition temperatures of the
 .  .compounds. To estimate the stability of HARMs in vivo, HARMs formed from Pro –Glu NHC H were incubated3 16 33 2
with DOPC liposomes or fetal calf serum at 408C. HARM size and shape did not change significantly, suggesting that such
lipopeptide particles can retain their morphology long enough in vivo to be useful as drug delivery vehicles. q 1998
Elsevier Science B.V. All rights reserved.
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1. Introduction
Liposomes are the most common form of self-as-
sembled microstructure that two-chain amphiphiles
adopt when dispersed in aqueous media. In some
cases, however, the molecular packing of am-
phiphiles produces bilayers that self-assemble into
particles with strikingly different geometries. Among
the most unusual of these lipid particles are high
 .axial ratio microstructures HARMs formed from
ribbons with differing degrees of helicity or rolled-up
bilayers. For example, the polymerizable phospho-
 .lipid, 1,2-bis 10,12-tricosadiynoyl -sn-glycero-3-
 .phosphocholine DC PC , forms cylindrical struc-8,9
tures called tubules. In this case, the structure appears
w xto be a helical ribbon, often with fused edges 1–5 .
In addition to DC PC, several other amphiphiles8,9
have been found to form HARMs. Among them are
derivatives of glutamic acid containing alkyl amines
amide linked to its a- and g-carboxyl groups and
w xbearing poly-glutamate or poly-aspartate 6,7 or short
w xpeptides 8 attached to its a-amino group. HARMs
were formed from the N-acyl and the N-a-hydroxy
w xfatty acyl fractions of galactocerebrosides 9 . Syn-
thetic and semi-synthetic sphingolipids can also be
w xmade to efficiently convert to HARMs 10 . Some
lipid mixtures containing phosphatidylserine convert
from liposomes to another HARM, the cochleate
2q w xcylinder, in the presence of Ca 11–13 . Tubules
and helices have also been found in aged suspensions
of saturated-chain phosphatidylcholines and as tran-
sient intermediates in the crystallization of choles-
w xterol from mixed micellar suspensions 14,15 .
A few attempts have been made to explore the
pharmaceutical potential of HARMs. It has been
suggested that the hollow lumen of DC PC tubules8,9
could be used for controlled release of biological
response modifiers such as growth factors and cy-
tokines to facilitate regeneration of wounded soft
w xtissue 16,17 . Encapsulation of transforming growth
factor-b into DC PC tubules with or without sub-8,9
sequent embedding of the tubules in agarose hydro-
.gel provides first-order release of the growth factor
over 10 h at 378C with preservation of biological
w x w xactivity 16,17 . Johnson et al. 18 have investigated
aerosol delivery of DC PC tubules using a Collison8,9
nebulizer, demonstrating that upon nebulization the
particles undergo only minor fragmentation. Signifi-
cant success has been achieved in development of
vaccines based on cochleate cylinders formed from
phosphatidylserine-containing lipid mixtures precipi-
tated by Ca2q. It has been shown that complexes of
such cochleate cylinders with peptides andror pro-
teins effectively stimulate antibody production and
cell-mediated immune responses in the absence of
additional adjuvants, particularly when administered
w xorally 12,13 . Apparently peptides and proteins im-
mobilized in this way are protected from proteolysis
in the stomach.
Based on their potential as pharmacologically ac-
tive molecules, we are studying the ability of lipopep-
w xtides to form HARMs 10 . Many peptides affect
w xbiological functions at very low concentrations 19 .
Because of this, peptides can be very effective drugs,
but practical pharmacological application of peptides
has been hampered by their very short half-life in
vivo, which is mostly due to filtration by the kidneys
w xandror proteolysis 19 . Because of their fast clear-
ance, and premature degradation, it is very difficult to
maintain peptides at concentrations within their thera-
peutic windows. The appropriate hydrophobic modi-
fication of biologically active peptides could cause
them to self-assemble to form HARMs, which will
serve as a drug depot. The lipopeptides might be
biologically active if their hydrophobic moieties do
not interfere with binding of the peptides to their sites
of action. Alternatively, the lipopeptides might func-
tion as prodrugs that become active after their hy-
drophobic moieties are cleaved.
The large dimensions of the HARMs make them
ideally suited for retention of drug at intramuscular,
subcutaneous, intraperitoneal, topical, and intrale-
sional sites. The tight molecular packing on the sur-
face of the structure might provide protection of the
biologically active peptides against premature prote-
olysis. The high curvature at the HARM edges sug-
gests much looser molecular packing in these regions.
If such bilayer edges are in contact with bulk solvent,
these regions are the most likely sites of dissolution
and enzymatic attack. We have shown that the tubule
morphology can lead to a nearly constant rate of
w xenzymatic hydrolysis of the surfactant 20 .
As a first step in the exploration of the pharmaceu-
tical potential of HARMs formed from lipopeptides,
we tested several approaches to quick and simple
formation of HARMs designed to be thermally stable
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under physiological conditions. We have used several
peptides bearing glutamic acid dialkyl amides
w  . xGlu NHC H as model compounds. Althoughn 2 nq1 2
the short peptide moieties of the amphiphiles studied
have no known biological activity, these compounds
should have physical properties close to those of
biologically active lipopeptides. We have chosen glu-
tamic acid dialkyl amides as a hydrophobic anchor
because of its known property to self-assemble into
HARMs when coupled to a number of short peptides
w x6–8 . We have synthesized some of these previously
reported lipopeptides as well as similar surfactants
with novel peptide head groups and varying lengths
of hydrocarbon chain. Since HARMs form only at
temperatures below the phase transition temperature
 .T , we have determined T values of the lipopep-m m
 .tides using differential scanning calorimetry DSC .
w xShimizu and Hato 8 have shown that sonicated
dispersions of some peptides lipidated with glutamic
acid dialkyl amides are capable of forming HARMs
spontaneously in pure water through ‘‘ . . . gradual
change from a very small particle to another specific
morphology over a period of hours or days . . . ’’. One
of our primary goals was to obtain similar particles in
a much shorter time. To this end, we applied methods
that form HARMs from one of the most studied
tubule forming compounds, the phospholipid
DC PC. These methods include thermal cycling of8,9
w xlipopeptide dispersions in aqueous media 1,21,22 or
 . w xin MeOH EtOH raqueous media mixtures 23 .
To insure biological compatibility of the resulting
suspensions, we used an aqueous medium at physio-
logical pH and ionic strength in all experiments. To
determine if HARMs have the potential for phar-
macologically useful lifetimes for continuous release
in vivo, HARMs formed from one of the compounds
were challenged by exposure to solutions containing
potential acceptors for lipid molecules. The chal-
lenges included incubation in the presence of
 .dioleoylphosphatidylcholine DOPC liposomes,
which were introduced as model cell membranes, and
in the presence of fetal calf serum, modeling extracel-
lular fluids.
2. Materials and methods
All chemicals and solvents from commercial
sources were of reagent grade. All reactions were
carried out under argon. Amino acids used were of
the L-configuration. Dioleoylphosphatidylcholine was
 .obtained from Avanti Polar Lipids Birmingham, AL .
 .Crude peptides, Boc-Gly-Lys- «-Z -Sar-Pro and Boc-
 .Lys- «-Z -Ala-Sar-Pro, were custom made by
 .Anaspec San Jose, CA and were purified by silica
gel chromatography. TLC was run on silica gel 60
 .F254 plates EM Science , and spots were visualized
with Cl ro-tolidine andror ninhydrin, andror I2 2
vapor. Flash chromatography was performed using
 .silica gel 60 230–400 mesh, EM Science . The
structures of intermediate compounds were confirmed
1  .by H NMR Brucker 200, 300, or 500 MHz . Mass
 .spectroscopy ES–MS was performed using a Kratos
Profile HV-4 instrument with an electrospray ioniza-
tion source, and samples were mixed with
 .MeOH:water 1:1 containing 1% acetic acid.
2.1. Synthesis
Several lipopeptides were synthesized, and their
chemical structures are shown in Fig. 1. Compounds
were synthesized according to the scheme in Fig. 2
using either DEPC, EDC, or DCC as the coupling
reagent.
( ) ( )2.1.1. HClP Pro –Glu NHC H3 14 29 2
A solution of Boc–Pro–Pro 29.31 mg, 93.82
.  .mmol in CH Cl 0.4 ml was mixed with HClP2 2
 .  .Pro–Glu NHC H 60.0 mg, 89.4 mmol dis-14 29 2
 .solved in DMF:CHCl 1.0 ml:1.6 ml , and the mix-3
ture was cooled to 08C with stirring. DEPC 16.0 mg,
.  . 98.3 mmol in DMF 0.3 ml and TEA 79.4 ml,
.  .196.6 mmol in DMF 0.3 ml were added. The
mixture was stirred at room temperature for 24 h
 .before diluting with CHCl 50 ml and was washed3
 .successively with saturated NH Cl 3=10 ml , H O4 2
Fig. 1. Schematic representation of lipopeptide compounds syn-
 .thesized. RsPro, Pro , Gly-Lys-Sar-Pro, and Ac-Lys-Ala-Sar-3
 .Pro. The value of n was 11, except in the case of the Pro R3
headgroup, in which case n was 11, 13, or 15.
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 .  .  .  .Fig. 2. The three synthetic schemes employed. HClP Pro –Glu NHC H and HClP Pro –Glu NHC H were prepared using3 12 25 2 3 16 33 2
scheme A.
 .  .1=10 ml , saturated NaHCO 3=10 ml , H O3 2
 .  .1=10 ml , brine 1=10 ml , and dried over
Na SO . After filtration, the solvent was evaporated2 4
in vacuo, and the residue was purified by flash
chromatography on silica gel with CHCl :MeOH3
 . 97.5:2.5 to give the product in 83% yield. TLC 9:1
. CHCl :MeOH : R 0.49. The product 60.0 mg, 89.43 f
.  .mmol was deprotected in CH Cl 1.5 ml with 4 M2 2
 .HClrdioxane 2 ml at room temperature for 2 h,
concentrated, dried in vacuo, and lyophilized from
 .  .A CN rH O 1:3 to give H Cl P Pro –2 3
 . Glu NHC H in 100% yield. TLC 4:1:114 29 2
. wbutanol:acetic acid:H O : R 0.43. ES–MS: Mq2 f
xq w xq2H 830.0, calcd. 830.3, Mq2H 415.5, calcd.
415.5.
( )2.1.2. HClPPro–Glu NHC H14 29 2
 .To a solution of Boc–Pro 44.0 mg, 204.5 mmol
 .  . in CHCl 2 ml , Glu NHC H 100.0 mg, 185.93 14 29 2
.  .mmol and HOBT 39.2 mg, 204.5 mmol were
added, and the mixture was cooled to 08C with
stirring. After the addition of EDC 39.2 mg, 204.5
.  .mmol and DIEA 35.6 ml, 204.5 mmol , the stirring
was continued for 2 h at 08C, and then at room
( )K.C. Lee et al.rBiochimica et Biophysica Acta 1371 1998 168–184172
temperature overnight. The mixture was diluted with
 .CHCl 40 ml and washed successively with satu-3
 .  .rated NH Cl 2=20 ml , H O 1=20 ml , saturated4 2
 .  .NaHCO 2=20 ml , H O 1=20 ml , and brine3 2
 .1=20 ml . Subsequent to drying over Na SO , the2 4
solvent was evaporated in vacuo, and the residue was
purified by flash chromatography with CHCl :MeOH3
 .  .97:3 to give 91% yield. TLC 97:3 CHCl :MeOH :3
R 0.15. Deprotection of the product 104 mg, 141.5f
.  .mmol in CH Cl 2.5 ml was achieved with 4 M2 2
 .HClrdioxane 2.5 ml at room temperature for 1.5 h.
The mixture was concentrated and dried in vacuo to
 .give HClPPro–Glu NHC H in 100% yield. TLC14 29 2
 .9:1 CHCl :MeOH : R 0.25.3 f
( )2.1.3. Glu NHC H14 29 2
 .Tetradecylamine 0.92 g, 4.31 mmol was com-
 . bined with a solution of Z-Glu OSu 1.0 g, 2.12
.  .mmol in CHCl 25 ml , and the reaction mixture3
w xwas stirred at room temperature for 2 days 8 . The
 .mixture was diluted with CHCl 100 ml and washed3
 .successively with saturated NaHCO 2=30 ml ,3
 .  . H O 1=30 ml , 5% HCl 2=30 ml , H O 1=302 2
.  .ml , and brine 1=20 ml . Subsequent to drying
over Na SO , the solvent was evaporated, the residue2 4
solidified from MeOH, and further purified by flash
 .chromatography with CHCl :MeOH 97:3 to give3
the product in 56% yield. The product was depro-
w xtected as described by Shimizu and Hato 8 for the
 .preparation of HBrPGlu NHC H . The depro-12 25 2
tected product was then filtered, washed with a small
amount of AcOH, suspended in ethyl ether, filtered,
 .and dried in vacuo. Desalting of the product 0.75 g ,
 .HBrPGlu NHC H , was achieved by partitioning14 29 2
 . with CHCl 80 ml and saturated NaHCO 3=203 3
. ml . The organic layer was washed with H O 1=202
.ml , dried over Na SO , and the solvent was evapo-2 4
 .rated to dryness to give Glu NHC H in 84%14 29 2
 . 1yield. TLC 9:1 CHCl :MeOH : R 0.30. H NMR3 f
 . w  . xCDCl rTMS : d 7.33 – CH –NH–CO– , 6.113 2 11
 .  .  . H N– , 3.40 a-CH– , 3.22 NH–C H – , 2.32 g-2 2
.  . w  . x CH – , 1.95 b-CH – , 1.50 – CH – , 0.88 –2 2 2 10
.CH –CH .2 3
( )2.1.4. Z-Glu OSu 2
 .  .Z-Glu 5.0 g, 17.8 mmol in dry THF 100 ml was
 .combined with OSu 4.64 g, 40.3 mmol and the
mixture was cooled to 08C with stirring. DCC 7.69
.g, 37.3 mmol was added, and the stirring was con-
tinued for several hours at 08C, and then at room
temperature overnight. DCU was removed by filtra-
tion, the solvent evaporated, and the residue was
taken up in ethyl acetate and filtered again. The
filtrate was washed with NaHCO , H O, brine, and3 2
dried over Na SO . Upon evaporation of the solvent,2 4
the residue was solidified from ethyl ether to give
 . 1 Z-Glu OSu in 87% yield. H NMR 300 MHz,2
.  .  .CDCl rTMS : d 7.35 C H – , 5.64 NH , 5.123 6 5
 .  . 
–CH –C H , 4.88 a-CH , 2.80 g-CH and –N–2 6 5 2
.  .  .CO–CH –CH –CO– , 2.45 b-CH , 2.33 b-CH .2 2
( ) ( )2.1.5. HClP Pro –Glu NHC H3 12 25 2
The synthesis of this compound has been reported
w xby Shimizu and Hato 24 . However, we have pre-
pared this compound via different routes of synthesis
and purification. A solution of Boc–Pro–Pro 36.3
.  .mg, 116.1 mmol in DMF 300 ml was mixed with
 .  .HClPPro–Glu NHC H 68.0 mg, 110.5 mmol12 25 2
 .  .in DMF 2 ml at 08C. DEPC 19.8 ml, 121.6 mmol
 .  .in DMF 300 ml and TEA 33.9 ml, 243.1 mmol in
 .DMF 300 ml were added, and stirring continued for
1 h at 08C, and then at room temperature overnight.
The mixture was washed and purified as described
 .  .for HClP Pro –Glu NHC H to give the prod-3 14 29 2
 .uct in 71% yield. TLC 9:1 CHCl :MeOH : R 0.49.3 f
 .The protected peptide lipid 68 mg, 77.9 mmol in
 .CH Cl 1.5 ml was stirred with 4 M HClrdioxane2 2
 .2 ml at room temperature for 1.5 h, concentrated,
 .and dried in vacuo to give HCl P Pro –3
 .Glu NHC H in 100% yield. M.p. 58–608C. TLC12 25 2
 . w xq9:1 CHCl :MeOH : R 0.30. ES–MS: MqH3 f
w xq2773.6, calcd. 774.2, MqH 387.5, calcd. 387.6.
( )2.1.6. HClPPro–Glu NHC H12 25 2
 . Boc–Pro 46.89 mg, 0.22 mmol and HOBT 29.4
.m g, 0.22 m m ol w ere com bined w ith
 .  .Glu NHC H 100 mg, 0.21 mmol in 3 ml12 25 2
 .CHCl rCH Cl 2:1 , and the mixture was cooled to3 2 2
 .08C. EDC 43.8 mg, 0.23 mmol was added, and the
mixture stirred for 1 h at 08C, and then at room
temperature overnight. The solution was washed and
 .purified as described for Boc–Pro–Glu NHC H14 29 2
to give the product in 80% yield. The protected
 .  .peptide lipid 111 mg, 0.16 mmol in CH Cl 1 ml2 2
 .was stirred with 4 M HClrdioxane 1 ml at room
temperature for 1 h, concentrated, and purified by
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 .flash chromatography with CHCl :MeOH 9:1 to3
 .give HClPPro–Glu NHC H in 82% yield. TLC12 25 2
 . w xq9:1 CHCl :MeOH : R 0.20. ES–MS: MqH :3 f
579.6, calcd. 579.9.
( )2.1.7. Glu NHC H12 25 2
This compound was prepared as described for
 . Glu NHC H to give 69% yield. TLC 9:114 29 2
. 1  .CHCl :MeOH : R 0.30. H NMR CDCl rTMS : d3 f 3
w  . x  . 7.33 – CH –NH–CO– , 6.12 H N– , 3.42 a-2 11 2
.  .  . CH– , 3.23 NH–C H – , 2.32 g-CH – , 1.94 b-2 2
. w  . x  .CH – , 1.50 – CH – , 0.89 –CH –CH .2 2 10 2 3
( ) ( )2.1.8. HClP Pro –Glu NHC H3 16 33 2
 .  .Boc– Pro –Glu NHC H was prepared as de-3 16 33 2
 .  .scribed for Boc– Pro –Glu NHC H to give3 14 29 2
 .84% yield. TLC 9:1 CHCl :MeOH : R 0.49. The3 f
removal of Boc was achieved as described for HClP
 .  .  .Pro –Glu NHC H to give HCl P Pro –3 14 29 2 3
 . Glu NHC H in 99.6% yield. TLC 4:1:116 33 2
. w xqBuOH:AcOH:H O : R 0.43. ES–MS: MqH2 f
w xq2885.7, calcd. 885.9, Mq2H 443.5, calcd. 443.5.
( )2.1.9. HClPPro–Glu NHC H16 33 2
This compound was prepared as described for
 .HClPPro–Glu NHC H to give 85% yield. TLC14 29 2
 .9:1 CHCl :MeOH : R 0.21.3 f
( )2.1.10. Glu NHC H16 33 2
This compound was prepared as described for
 Glu NHC H to give 93% yield. TLC 9:114 29.2
. 1  .CHCl :MeOH : R 0.30. H NMR CDCl rTMS : d3 f 3
w  . x  . 7.37 – CH –NH–CO– , 6.15 H N– , 3.45 a-2 11 2
.  .  . CH– , 3.22 NH–C H – , 2.34 g-CH – , 1.95 b-2 2
. w  . x  .CH – , 1.50 – CH – , 0.88 –CH –CH .2 2 10 2 3
( )2.1.11. Ac-Lys-Ala-Sar-Pro-Glu NHC H PHBr12 25 2
 .Acetic anhydride 7.53 ml, 79.78 mmol and TEA
 .11.12 ml, 79.78 mmol were added to the ice-H O2
 .cooled solution of HCl P Lys- «-Z -Ala-Sar-Pro-
 .  . Glu NHC H 65.4 mg, 66.49 mmol in DMF 212 25 2
.ml and stirred for 1.25 h, and then at room tempera-
 .ture overnight. Upon dilution with CHCl 20 ml ,3
the mixture was washed as described for HClP
 .  .Pro –Glu NHC H and purified by flash chro-3 14 29 2
 .matography with CHCl :MeOH 95:5 to give the3
 .product in 97% yield. TLC 9:1 CHCl :MeOH : R3 f1  .  .0.25. H NMR DMSO-d rTMS : d 8.20–7.20 NH ,6
 .  .7.35 CH –C H – , 5.01 CH –C H , 4.80–3.492 6 5 2 6 5
 .  .a-CH , 3.12–2.93, 2.79 NH–CH –CH , N–CH ,2 3 3
 . w  . x1.84 CH CO– , 1.50–1.20 – CH – , 1.20, 1.103 2 10
 .   . . b-CH , 0.86 – CH –CH – . The product 66.03 2 11 3
.  .mg, 64.4 mmol in CHCl 2 ml was deprotected by3
 .treatment with 30% HBrrAcOH 5 ml at room
temperature for 2 h. After the solvent evaporation,
the residue was dried in vacuo and lyophilized from
 .MeOH:ACN:H O 1:1:2 to give the product in2
 .64.2% yield. TLC 4:1:1 BuOH:AcOH:H O : R2 f1  .0.33. M.p.: 130–1348C. H NMR DMSO-d rTMS :6
 .  .d 8.4–7.5 NH , 4.80–3.75 a-CH , 3.04–2.97,
 .  .2.84–2.72 –NH–CH – , 1.84 CH –CO– , 1.36–2 3
w  . x  . w1.24 – CH –CH , 1.20, 1.10 b-CH , 0.85 –2 10 3 3
 . .x w xqNH– CH –CH . ES–MS: MqH 892.1 calcd.2 11 3
w xq2892.30, Mq2H 446.1, calcd. 446.65.
( ) ( )2.1.12. HClPLys- «-Z -Ala-Sar-Pro-Glu NHC H12 25 2
 . Boc-Lys- «-Z -Ala-Sar-Pro 100.0 mg, 161.3
.  . mmol was coupled to HBrPGlu NHC H 82.512 25 2
.  .mg, 146.6 mmol as described for HClP Pro –3
 .Glu NHC H . The product was purified by flash14 29 2
 .chromatography with CHCl :MeOH 96:4 to give3
 .the product in 58% yield. TLC 9:1 CHCl :MeOH :31  .R 0.44. H NMR DMSO-d rTMS : d 8.21–6.80f 6
 .  .  .NH , 7.34 CH –C H , 5.00 CH –C H , 4.80–2 6 5 2 6 5
 .  .3.45 a-CH , 3.10–2.90, 2.79 NH–CH -, N–CH ,2 3
w  . x w . x1.47–1.13 – CH – , 1.36 CH C– , 1.19, 1.102 10 3 3
 . w  . xb-CH , 0.85 – CH –CH . The peptide lipid3 2 11 3
was deprotected with 4 M HClrdioxane as described
 .  .for HClP Pro –Glu NHC H and purified by3 14 29 2
 .flash chromatography with CHCl :MeOH 9:1 to3
 .  .give HCl P Lys- «-Z -Ala-Sar-Pro-Glu NHC H12 25 2
 . 1in 81% yield. TLC 9:1 CHCl :MeOH : R 0.26. H3 f
 .  .NMR DMSO-d rTMS : d 8.34–7.14 NH , 7.346
 .  .  .CH –C H , 5.00 CH –C H , 4.80–3.42 b-CH ,2 6 5 2 6 5
 . w3.12–2.90, 2.78 NH–CH –, N–CH , 1.45–1.20 –2 3
 . x  . w  .CH – , 1.19, 1.10 b-CH , 0.85 – CH –2 10 3 2 2
.CH .3
( )2.1.13. 2HBrPGly-Lys-Sar-Pro-Glu NHC H12 25 2
 .  .Boc-Gly-Lys- «-Z -Sar-Pro 70 mg, 115.38 mmol
 . was coupled to Glu NHC H 52.9 mg, 109.8812 25 2
.  .m m ol as described for H C l P Pro –3
 .Glu NHC H to give the product in 96% yield.14 29 2
 . TLC 9:1 CHCl :MeOH : R 0.36. The product 453 f
.  .mg, 42.1 mmol was dissolved in CH Cl 1 ml and2 2
deprotected by treatment with 30% HBrrAcOH 9
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.ml at room temperature for 2 h. Evaporation of the
solvent and lyophilization gave 2HBrPGly-Lys-Sar-
 . Pro-Glu NHC H in 80% yield. TLC 4:1:112 25 2
. w xqBuOH:AcOH:H O : R 0.31. ES–MS: MqH2 f
836.0, calcd. 836.7.
[ 3 ]( ) ( )2.1.14. HClP 5- H Pro –Glu NHC H3 16 33 2
 .To a solution of HClPPro–Pro–Glu NHC H16 33 2
 .  . w48.8 mg, 59.14 mmol in CHCl 3 ml , Boc- 5-3
3 x  . H Pro 14.0 mg, 65.06 mmol and HOBT 8.8 mg,
.65.06 mmol were added. Upon cooling the mixture
 .to 08C, EDC 12.47 mg, 65.06 mmol and DIEA
 .21.63 ml, 124.20 mmol were added, and the mix-
ture was stirred at 08C for 45 min before allowing to
warm up to room temperature overnight. The reaction
 .solution was diluted with CHCl 30 ml and washed3
with saturated NH Cl, H O, saturated NaHCO ,4 2 3
H O, brine, dried over Na SO , and concentrated2 2 4
under reduced pressure. The residue was further puri-
fied by flash chromatography with CHCl :MeOH3
 .97.5:2.5 to give the product in 93% yield. The
 .protected peptide lipid 54.2 mg, 54.9 mmol was
 .deprotected using 4 M HClrdioxane 2.5 ml at room
temperature for 2 h, concentrated, and dried in vacuo
w 3 x .  .to give HClP 5- H Pro –Glu NHC H in 100%3 16 33 2
yield. The product co-migrated with the unlabeled
 .  .HClP Pro –Glu NHC H on TLC plate and is3 16 33 2
estimated to be 97.5% radiochemically pure by TLC
 .and fluorography. TLC 4:1:1 BuOH:AcOH:H O :2
R 0.43.f
[ 3 ]2.1.15. Boc- 5- H Pro
Synthesis of this compound is a modification of
w x w 3 x the procedure of Tarbell et al. 25 . 5- H Pro 1 mCi,
.  .specific activitys15 Cirmmol in H O 500 ml2
 . was diluted with unlabeled Pro 11.5 mg . Dioxane 1
.ml was added to the mixture followed by 1 N NaOH
 .100 ml . Upon cooling the stirred mixture to 08C,
 .  .Boc O 24.0 mg, 109.9 mmol was added, and the2
mixture was allowed to warm up to room temperature
overnight. The solution was diluted with H O 402
.  .ml and washed with hexane 3=10 ml . CH Cl2 2
 .10 ml was added to the aqueous layer and cooled to
08C. The pH was adjusted to 1–2 with 1 N HCl, and
 .the product was extracted with CH Cl 5=15 ml .2 2
The combined CH Cl extracts were washed with2 2
 .H O 2=15 ml , dried over Na SO , concentrated2 2 4
under reduced pressure, and dried in vacuo to give
w 3 x  .Boc- 5- H Pro specific activitys10 Cirmole in
65% yield. The product co-migrated with the unla-
beled compound on TLC plate. TLC 9:1
.CHCl :MeOH : R 0.25.3 f
( )2.1.16. HClPPro–Pro–Glu NHC H16 33 2
 .Boc–Pro–Pro 57.86 mg, 185.2 mmol was cou-
 .  .pled to Glu NHC H 100.0 mg, 168.3 mmol as16 33 2
w 3 x .  .described for HClP 5- H Pro –Glu NHC H .3 16 33 2
The product was purified by flash chromatography
 .with CHCl :MeOH 97.5:2.5 to give Boc-Pro-Pro-3
 . Glu NHC H in 100% yield. TLC 95:516 33 2
.CHCl :MeOH : R 0.30. The deprotection of Boc3 f
wwas achieved also as described for HCl P 5-
3 x .  .H Pro –Glu NHC H to give HClPPro–Pro–3 16 33 2
 . Glu NHC H in 79% yield. TLC 4:1:116 33 2
.BuOH:AcOH:H O : R 0.42.2 f
2.2. Differential scanning calorimetry
To prepare samples for DSC, 70 ml of 20 mM
HEPES, 120 mM NaCl, 1 mM EDTA, 0.2% NaN ,3
 .pH 7.4 HBS was added to 1.0–2.0 mg of lipopep-
tide powders. The pH of the resulting suspensions
was adjusted to 7.4 using 0.1 M NaOH. These sus-
pensions were weighed and sealed in 70 ml silver
calorimetry pans in aliquots containing 50 mg of
HBS. A pan of the same type with 50 mg of HBS
only was used as a reference. In the case of Ac-Lys-
 .  .Ala-Sar-Pro-Glu NHC H and Pro –12 25 2 3
 .Glu NHC H , additional DSC measurements16 33 2
were made in the presence of 46% EtOH and 30%
MeOH respectively. DSC was performed using a
Seiko DSC-100 high sensitivity calorimeter Tor-
.rance, CA . Samples were heated from 38C to 958C at
18Crmin. DSC of each sample was run twice. Re-
ported T values were recorded during the secondm
run. The first run was used to insure proper hydration
of the peptide lipids.
To determine the integrity of the compounds after
thermal scanning, the DSC pans were opened and
their contents dissolved in MeOH to make solutions
with final concentrations of the lipopeptides of 0.5
mgrml. The solutions were analyzed by TLC in
 .BuOH:AcOH:H O 4:1:1 . TLC revealed no decom-2
position of the studied compounds after DSC.
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2.3. Preparation of HARMs
HARMs were formed either by thermal cycling of
dispersions of the compounds in HBS, or by thermal
cycling of HBS dispersions in the presence of MeOH
or EtOH, or by precipitation upon dilution of concen-
trated MeOH solutions of the compounds with HBS.
When alcohols were used for HARM preparation, the
particles were subsequently transferred to pure HBS
using centrifugal-driven filtration. To do this, 200 ml
aliquots of particle suspensions were centrifuged in
Ultrafreew-CL Centrifugal Filters with a 30,000 Da
nominal molecular weight limit Millipore, Bedford,
.MA for 15 min at 3000=g at room temperature,
washed with 1 ml of fresh HBS under the same
conditions, and reconstituted in the original volume
of HBS.
2.3.1. Heating and cooling of aqueous dispersions
 .Samples of 0.5 mg of either Pro –3
 .  .  .Glu NHC H or Pro –Glu NHC H in 114 29 2 3 16 33 2
ml of HBS each were sonicated for 15 s at room
temperature using a high power bath sonicator
 .Laboratory Supplies, Hicksville, NY . Dispersions
obtained were rapidly heated to 658C, incubated for
15 min, then cooled to room temperature at 0.28Crin
in an RTE-110P programmable water bath Neslab
.Instruments, Newington, NH .
2.3.2. Heating and cooling of HBS dispersions in the
presence of MeOH
 .Samples of either 0.1 mg of Pro –3
 .  .  .Glu NHC H or Pro –Glu NHC H dis-14 29 2 3 16 33 2
solved in 20 ml of MeOH each were added to 200 ml
of HBS while vortexing. Concentrations of MeOH in
the samples were adjusted to the values shown in Fig.
4. Sealed samples were heated to 658C, incubated for
15 min and then cooled to room temperature at
0.28Crmin. In the case of Boc-protected intermedi-
ates listed in Table 4, 0.3 mgrml dispersions of the
compounds in 30% MeOH in HBS, obtained as
described below, were used. Upon heating to 658C,
all dispersions formed semi-transparent solutions.
2.3.3. Precipitation upon dilution of concentrated
MeOH solution
Samples of 0.2 mg of Gly-Lys-Sar-Pro-
 .  .  .Glu NHC H or Pro –Glu NHC H dis-12 25 2 3 12 25 2
solved in 40 ml of MeOH were rapidly added to 400
ml of HBS while vortexing; the mixtures were then
incubated for 2 h at room temperature. Aliquots of
 .0.5 ml of the intermediates Table 4 dissolved in
MeOH in concentrations of 1 mgrml were added to
1.2 ml of HBS while vortexing, and incubated
overnight at room temperature.
2.3.4. Heating and cooling of HBS dispersions in the
presence of EtOH
Samples of 0.2 mg of Ac-Lys-Ala-Sar-Pro-
 .G lu N H C H , G ly - L y s - S a r - P r o -1 2 2 5 2
 .  .  .Glu NHC H , or Pro –Glu NHC H were12 25 2 3 12 25 2
dissolved in 50 ml of EtOH. The minimum fractions
of HBS that induced precipitation of the lipopeptides
were determined by addition of HBS in 10 ml por-
tions while vortexing, with 5 min incubations after
each addition. The critical concentrations of EtOH for
each compound are shown in Table 1. Dispersions
obtained by HBS precipitation were heated to 508C,
incubated for 15 min, then cooled rapidly to room
 .temperature 508C to 208C within 4 min .
2.4. Morphology
The morphology of the precipitates was studied
using a Zeiss ICM-405 inverted phase contrast micro-
 .scope Carl Zeiss, Thornwood, NY equipped with a
Dage 66 SIT video camera Dage-MTI, Michigan
.City, IN . Images obtained were digitized using a
Data Translation QuickCapture frame grabber board
in a Macintosh II. In addition, the precipitates were
 .studied by transmission electron microscopy TEM .
Samples for TEM were prepared by applying 20 ml
aliquots of suspensions to Formvar-coated 150 mesh
copper TEM sample grids. No stain was used. The
samples were dried in air for at least 24 h before
observation with a Philips EM 410 transmission elec-
Table 1
Final concentrations of EtOH at which precipitation occurs upon
dilution of 4 mgrml solutions of the lipopeptides with HBS
Compound Concentration of EtOH
 .volume %
 .Ac-Lys-Ala-Sar-Pro-Glu NHC H 4612 25 2
 .Gly-Lys-Sar-Pro-Glu NHC H 4212 25 2
 .  .Pro –Glu NHC H 363 12 25 2
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tron microscope. The outer dimensions of HARMs
were measured using NIH Image 1.58 software.
( ) ( )2.5. Light scattering of Pro –Glu NHC H3 16 33 2
HARMs as a function of temperature
 .Light scattering at 300 nm of Pro –3
 .Glu NHC H HARM suspension was measured16 33 2
using an LS-5B fluorescence spectrometer Perkin-
.Elmer equipped with a magnetic stirrer and a ther-
mostated cuvette holder. An aliquot of 0.4 mM
 .  .Pro –Glu NHC H HARMs in 30% MeOH in3 16 33 2
 .HBS obtained by heating and cooling see above
was heated from 258 to 758C in 2–58C steps in a
sealed cuvette. The temperature of the suspension
was measured using a thermocouple inserted through
a septum in the cuvette cap. The sample temperature
was allowed to stabilize for 5–10 min after each step.
The data obtained were fit to a sigmoidal Boltz-
.mann function.
 .The same experiment was done with Pro –3
 .Glu NHC H HARMs transferred to pure HBS16 33 2
using an Ultrafreew-CL Centrifugal Filter. In order to
 .estim ate the concen tra tion o f P ro –3
 .Glu NHC H after MeOH removal, the lipidated16 33 2
w 3 x  .peptide was doped with a trace of 5- H - Pro –3
 .  .Glu NHC H . The yield of MeOH free Pro –16 33 2 3
 .Glu NHC H , estimated by scintillation count-16 33 2
 .ing, was found to be 62"0.43% ns3 . This value
 .was used to adjust the concentration of Pro –3
 .Glu NHC H to 0.4 mM.16 33 2
( ) ( )2.6. Stability of Pro –Glu NHC H HARMs3 16 33 2
 .  .A suspension of Pro –Glu NHC H HARMs3 16 33 2
formed by heating and cooling of the lipopeptide in
 .HBSrMeOH see above was added to either fetal
calf serum or sonicated DOPC liposomes in HBS at
pH 7.4 at a DOPC concentration of 5 mgrml at a
 .ratio of 1r10 vrv . The resulting suspensions were
incubated for 45 h at 408C.
3. Results and discussion
 .  .Two lipopeptides, Pro –Glu NHC H and3 12 25 2
 .Gly-Lys-Sar-Pro-Glu NHC H , reported by12 25 2
w xShimizu and Hato 8 were chosen as ‘control lipo-
peptides’ for generating HARMs. The lengths of the
alkyl chains were increased by 2 and 4 carbons with
the same head group to study the dependence of their
hydrocarbon chain melting temperature, T , on chainm
length, as well as to find peptide lipids with conve-
nient melting temperatures for future in vivo studies.
 .Ac-Lys-Ala-Sar-Pro-Glu NHC H , a variant with12 25 2
a potential tryptic cleavage site in which the a-amino
terminus was blocked, was also prepared. The
lipopeptide, however, proved to be a very poor sub-
 .strate for trypsin data not shown .
Both Sar and Pro provide challenges as structural
elements for surfactant headgroups. 1H NMR of
 .2HBr P Gly-Lys-Sar-Pro-Glu NHC H and Ac-12 25 2
 . Lys-Ala-Sar-Pro-Glu NHC H PHBr as well as12 25 2
.the peptides without hydrocarbon chains exhibited
multiple resonance peaks that were further investi-
gated by COSY. The cross peaks indicated that the
 .lipopeptides and the corresponding peptide exist in
multiple, stable conformational isomers on the NMR
time scale. The existence of cisrtrans isomers of Sar
and Pro containing cyclic peptides has been previ-
w xously documented 26 . The existence of multiple
structures due to cisrtrans isomerization of N-sub-
stituted peptide bonds was evident even in such short
linear sequences. The exact nature of these isomers
and their influence on head group-head group interac-
tions in HARMs such as tubules have not yet been
investigated.
3.1. DSC
The value of T must be known to develop proto-m
cols for forming, storing, and observing HARMs. To
determine T , DSC of the lipopeptides dispersed inm
HBS was performed. Each compound gave a single
endothermic peak on heating in the range of 38C to
958C. The phase transitions are summarized in Table
 .  .2. The T value for Pro –Glu NHC H is closem 3 12 25 2
to that previously reported for this compound in pure
 w x.water at pH 5–6 318C, Shimizu and Hato 8 ,
w hereas the value for G ly-Lys-Sar-Pro-
 .Glu NHC H is slightly different from the re-12 25 2
 w x.ported value 398C, Shimizu and Hato 8 . This
suggests that the presence of the extra NH group2
 .due to the Lys makes this class of compounds more
sensitive to the environment, e.g., pH and ionic
strength, compared to those with only prolines. All
( )K.C. Lee et al.rBiochimica et Biophysica Acta 1371 1998 168–184 177
Table 2
Phase transition temperatures as determined by DSC from the
endotherm maxima in heating scans
Compound Solvent Tm
 .8C
 .  .Pro –Glu NHC H HBS 34.63 12 25 2
 .  .Pro –Glu NHC H HBS 51.23 14 29 2
 .  .Pro –Glu NHC H HBS 61.73 16 33 2
 .  .Pro –Glu NHC H 30% MeOH 59.73 16 33 2
in HBS
 .Gly-Lys-Sar-Pro-Glu NHC H HBS 50.112 25 2
 .Ac-Lys-Ala-Sar-Pro-Glu NHC H HBS 67.612 25 2
 .Ac-Lys-Ala-Sar-Pro-Glu NHC H 46% EtOH 29.512 25 2
in HBS
 .  .lipopeptides tested except Pro –Glu NHC H3 12 25 2
 .have T values higher than 378C. Pro derivativesm 3
with longer hydrocarbon chains have the higher Tm
values as anticipated. Since all HARMs observed to
date consist of lipids below their T values, HARMsm
formed from all but one of the compounds studied
here should be thermally stable at physiological tem-
peratures. Note that the DSC experiments were not
performed on pre-formed HARMs, so caution should
be used in predicting HARM melting temperatures
from these data.
3.2. HARM formation
The first approach tested for accelerating lipopep-
tide HARM formation was heating and cooling of
aqueous dispersions of the surfactant through T ,m
which has been demonstrated to be effective for
w xformation of DC PC tubules 1,21,22 . In the pre-8,9
 .sent study, HBS dispersions of Pro -containing am-3
phiphiles with different hydrocarbon chain lengths
 .  .  .  .  .  .  .  .Fig. 3. TEM images of particles formed with Pro –Glu NHC H I , Pro –Glu NHC H II , and Pro –Glu NHC H3 12 25 2 3 14 29 2 3 16 33 2
 .III after heating and slow cooling of these lipopeptides in HBS.
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were heated to 658C in HBS and cooled to room
temperature at 0.28Crmin. TEM images of the result-
ing particles are shown in Fig. 3. In this and in all
cases below, TEM results were consistent with obser-
vations made by optical microscopy. Heating and
 .slow cooling through T transforms Pro –m 3
 .Glu NHC H into helical ribbons with nearly12 25 2
100% efficiency. The width of these ribbons is simi-
lar to the helical pitch, but fusion of adjacent ribbon
edges is observed in rare cases. These HARMs have
an average diameter of 0.14"0.05 mm and lengths
 .of 7.0"2.5 mm Table 3 .
 .  .The morphology of Pro –Glu NHC H3 12 25 2
HARMs is close to that observed by Shimizu and
w xHato 8 in sonicated aqueous dispersions of the same
material in early stages of incubation. The major
difference between the results of Shimizu and Hato
and ours is that the HARMs formed by slow cooling
in this study did not change their morphology signifi-
cantly over time. The helical structures formed just
after cooling were present after storage for 6 months
 .at room temperature data not shown . In the study of
w xShimizu and Hato 8 , HARMs continued to convert
from helical ribbons to tubules and changed length
over time. Slow cooling through T , unlike incuba-m
tion at room temperature, causes self-assembly of
 .  .Pro –Glu NHC H molecules directly into3 12 25 2
HARMs with stable morphology. The fact that the
resulting HARMs are mostly helical ribbons, rather
than tubules, may be related to the presence of HBS
electrolytes in the formation mixture. Effects of ionic
strength on HARM formation have been predicted,
w xalthough not often observed 27–29 .
Slow cooling in HBS resulted in HARM formation
 .  .  .by Pro – G lu N H C H and Pro –3 14 29 2 3
 .Glu NHC H as well. However, the conversion16 33 2
efficiencies in these cases were much lower; signifi-
cant fractions of the material formed amorphous ag-
 .gregates Fig. 3 . This may be due to more rapid
precipitation of these longer chain, less soluble lipo-
peptides. In an attempt to increase the conversion
efficiencies, MeOH was included in the formation
 .  .  .medium. Pro –Glu NHC H and Pro –3 14 29 2 3
 .Glu NHC H were dispersed in MeOHrHBS16 33 2
mixtures with varying percentages of MeOH. The
influence of MeOH on HARM formation has been
studied previously with DC PC. It has been shown8,9
that cooling of DC PC dispersions in the presence8,9
of alcohols can result in more efficient tubule forma-
tion than that found with pure aqueous dispersions
w x  .  .23 . The data obtained on Pro –Glu NHC H3 14 29 2
 .  .and Pro –Glu NHC H are consistent with this3 16 33 2
finding. As shown in Fig. 4, slow cooling of lipopep-
tides in the presence of 30% or 50% MeOH increases
the efficiency of HARM formation to almost 100%.
It should be noted that only the particles formed in
30% MeOH are relatively straight and uniform in
size. Slow cooling in 50% MeOH induced formation
Table 3
Morphologies and dimensions of HARMs formed by various methods from the peptides modified with glutamic acid dialkyl amide
a a .  .Compound Formation method Morphology Length mm Diameter mm
b .  .  .  .Pro –Glu NHC H Slow cooling of HBS Helical ribbonsrtubules 7.0"2.5 ns10 0.14"0.05 ns73 12 25 2
dispersion
 .  .Dilution of MeOH Helical ribbonsrtubules 6.6"2.3 ns7 0.15"0.04 ns9
solution
 .  .  .  .Pro –Glu NHC H Slow cooling in 30% Helical ribbonsrtubules 7.8"2.9 ns7 0.22"0.02 ns53 14 29 2
MeOH in HBS
 .  .  .  .Pro –Glu NHC H Slow cooling in 30% Helical ribbonsrtubules 7.9"3.2 ns7 0.28"0.03 ns53 16 33 2
MeOH in HBS
 .  .  .Gly-Lys-Sar-Pro-Glu NHC H Dilution of MeOH Helical ribbons 3.1"0.3 ns7 0.12"0.02 ns512 25 2
solution
 .Cooling in 42% EtOH Rod-like aggregates )70 0.65"0.18 ns9
in HBS
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 .  .  .  .  .  .Fig. 4. TEM images of particles formed with Pro –Glu NHC H I and Pro –Glu NHC H II after heating and cooling of3 14 29 2 3 16 33 2
 .  .  .the lipopeptides in HBSrMeOH mixture with MeOH concentrations of 20% a , 30% b , and 50% c . Note: some tubules wrapped with
 .helical ribbons were observed in IIc as highlighted by arrow.
of ribbons with broad width variation; some ribbons
were tapered, and others were irregularly wound into
imperfect helices. Tubules were also observed in rare
cases. Formation of tubules in less than 30% MeOH
resulted in only partial conversion to HARMs. Parti-
 .  .cles obtained from Pro –Glu NHC H and3 14 29 2
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Table 4
Morphologies of HARMs formed from Boc-protected peptides modified with glutamic acid dialkyl amides
Compound Formation method Morphology
 .  .Boc-Gly-Lys- «-Z -Sar-Pro-Glu NHC H Dilution of MeOH solution Amorphous aggregates12 25 2
Slow cooling in 30% MeOH in HBS HARMs
 .  .Boc-Lys- «-Z -Ala-Sar-Pro-Glu NHC H Dilution of MeOH solution Amorphous aggregates12 25 2
Slow cooling in 30% MeOH in HBS HARMsramorphous aggregates
 .Boc–Pro–Glu NHC H Dilution of MeOH solution Amorphous aggregates14 29 2
Slow cooling in 30% MeOH in HBS HARMs
 .Boc–Pro–Glu NHC H Dilution of MeOH solution Amorphous aggregates16 33 2
Slow cooling in 30% MeOH in HBS HARMs
 .  .Boc– Pro –Glu NHC H Dilution of MeOH solution HARMsramorphous aggregates2 16 33 2
Slow cooling in 30% MeOH in HBS Amorphous aggregates
 .  .Boc– Pro –Glu NHC H Dilution of MeOH solution HARMsramorphous aggregates3 14 29 2
Slow cooling in 30% MeOH in HBS HARMsramorphous aggregates
 .  .Boc– Pro –Glu NHC H Dilution of MeOH solution HARMs3 16 33 2
Slow cooling in 30% MeOH in HBS HARMsramorphous aggregates
 .  .Pro –Glu NHC H by heating and cooling in3 16 33 2
30% MeOH had diameters of 0.22"0.02 mm and
lengths of 7.8"2.9 mm, and diameters of 0.28"0.03
mm and lengths of 7.9"3.2 mm, respectively Table
.3 . These HARMs have morphologies close to those
 .  .formed by Pro –Glu NHC H by heating and3 12 25 2
slow cooling in pure HBS. Transferring these HARMs
to pure HBS and consequent storage for up to 4
months at room temperature did not induce observ-
 .able changes in their morphology data not shown .
 .The interm ediate, protected Boc – Pro –3
 .  .  .Glu NHC H and Boc– Pro –Glu NHC H14 29 2 3 16 33 2
formed HARMs in 30% MeOH in HBS upon cooling
 .at 0.28Crmin as well Table 4, images not shown .
The morphology of particles was different in this
case. HARMs were not uniform in size, and amor-
phous aggregates were often observed. These results
give additional examples of the modification of pep-
tides with glutamic acid dialkylamides producing
HARMs. This also shows that a minor modification
in the peptide head group may affect the morphology
of HARMs obtained under a given set of formation
conditions.
Heating and cooling of DC PC aqueous disper-8,9
sions in the presence of EtOH induces tubule forma-
w xtion as well 23 . This approach for formation of
HARMs was applied to some of the lipopeptides. A
single concentration of EtOH was used for each
compound—the concentration at which the lipopep-
tide precipitates from solution in absolute EtOH upon
gradual addition of HBS at room temperature. Heat-
ing to 508C and fast subsequent cooling 508C to
.248C within about 4 in of the resulting suspensions
produced HARMs from both Ac-Lys-Ala-Sar-Pro-
 .G lu N H C H and G ly-L ys-S ar-P ro -12 25 2
 .  .Glu NHC H Fig. 5 . The compound formed a12 25 2
 .mixture of very long )70 mm and sometimes bent
rod-like aggregates with rather broad variations in
 .diameter Table 3 . Cooling at a slower rate, in this
case, did not significantly alter the morphology of the
 .particles data not shown . The rest of the compounds
 .processed this way, Pro–Glu NHC H and12 25 2
 .  . Pro –Glu NHC H , did not form HARMs not3 12 25 2
.shown . Although the highest temperature used in
this technique was lower than the T value of Ac-m
 .Lys-Ala-Sar-Pro-Glu NHC H in pure aqueous12 25 2
buffer, the fact that the alcohol-containing lipopeptide
suspension became semi-transparent as would be
.observed for a micellar suspension indicated that the
heating was sufficient to disperse the compound.
Direct DSC measurement demonstrated that, in fact,
 .Ac-Lys-Ala-Sar-Pro-Glu NHC H in HBS con-12 25 2
taining 46% EtOH has a major transition peak at
 .29.58C vs. 67.68C in pure HBS, Table 2 and no
transition above this value. The influence of EtOH on
the thermal behavior of Ac-Lys-Ala-Sar-Pro-
 .Glu NHC H is very close to that of )80%12 25 2
w xEtOH on DC PC 30 .8,9
Finally, we formed well-defined HARMs by addi-
 .tion of Gly-Lys-Sar-Pro-Glu NHC H and12 25 2
 .  .Pro –Glu NHC H methanolic solutions to3 12 25 2
 .  .HBS Fig. 6 . Gly-Lys-Sar-Pro-Glu NHC H12 25 2
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 .  .  .  .Fig. 5. Optical images of Ac-Lys-Ala-Sar-Pro-Glu NHC H I and Gly-Lys-Sar-Pro-Glu NHC H II particles formed after12 25 2 12 25 2
cooling of dispersions of the lipopeptides from 508C to 208C in EtOHrHBS mixtures with EtOH concentrations as shown in Table 1.
forms helical ribbons with an average width of 0.12
 ."0.02 mm and lengths of 3.1"0.34 mm Table 3 .
 .  .Pro –Glu NHC H forms HARMs with mor-3 12 25 2
phology and dimensions very close to those obtained
 .by slow cooling Table 3 .
The ability of some intermediate Boc-protected
lipopeptides to form HARMs was tested using MeOH
 .precipitation Table 4, images not shown . All of
these compounds form HARMs. Although the
HARMs formed were not always uniform in size and
 .  .Fig. 6. TEM images of the particles formed by the dilution of MeOH solution method: Gly-Lys-Sar-Pro-Glu NHC H I ;12 25 2
 .  .  .Pro –Glu NHC H II .3 12 25 2
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were often contaminated with amorphous precipi-
tates, the results obtained strongly suggest that glu-
tamic acid dialkylamides can be used as an universal
lipid anchor to construct molecules capable of self-
assembling into HARMs from a broad range of pep-
tides.
3.3. Light scattering studies
Ratna et al. reported two distinct mechanisms of
tubule formation upon slow cooling of DC PC in8,9
MeOHrwater mixtures. Light scattering and polar-
ized optical microscopy studies showed that at lower
concentrations of lipid, tubules form directly from the
isotropic phase of the lipid, whereas at higher concen-
trations, the formation of tubules is preceded by
w xaggregation of the lipid into an L phase 23 . It hasa
been shown later that in MeOHrH O mixtures, the2
first mechanism leads to formation of mostly single
bilayer tubules, and the second forms tubules contain-
w xing 2–4 bilayers 31 , thus providing a valuable tool
for tailoring the tubule lamellarity for a particular
application.
In order to examine if HARM formation proceeds
by either of these mechanisms, we studied the light
 .  .scattering of a Pro –Glu NHC H HARM sus-3 16 33 2
pension in the formation solution 30% MeOH in
.  .HBS as a function of temperature Fig. 7 . Light
Fig. 7. Light scattering as a function of temperature of 0.4 mM
 .  . Pro –Glu NHC H in HBS squares, dashed line—3 16 33 2
.  .  .sigmoidal fit ; 0.4 mM Pro –Glu NHC H in 30% MeOH3 16 33 2
 .  .in HBS circles, solid line—sigmoidal fit ; HBS down triangles ;
 .30% MeOH in HBS up triangles .
scattering sharply decreases at about 608C. This
clearly indicates that upon heating to the T , HARMsm
 .convert into one or more structure s of much smaller
 .size. The light scattering of the Pro –3
 .Glu NHC H suspension above the transition16 33 2
temperature is about 45 times higher than the back-
ground scattering of 30% MeOH in HBS containing
no lipid. This demonstrates that, immediately above
 .  .the transition temperature, Pro –Glu NHC H3 16 33 2
molecules in this solvent do not form an isotropic
phase, but are still self-assembled into some kind of
aggregate. These aggregates are not visible in the
 .phase contrast microscope 63= magnification sug-
gesting that they may be micelles. No particles were
detected by optical microscopy in samples heated to
658C and observed at room temperature within ap-
proximately 2 min. After that time, the lipidated
peptide precipitated as amorphous aggregates. Ac-
w xcording to Ratna et al. 23 , upon heating DC PC to8,9
;208C above its tubule–non-tubule transition, an
isotropic phase forms with light scattering equal to
that of the MeOHrwater mixture alone. The light
 .  .scattering of Pro –Glu NHC H at the concen-3 16 33 2
tration studied was the same in the 62–788C range
 .Fig. 7 , suggesting that smaller aggregates formed
from these HARMs immediately above the transition
temperature do not change size upon further heating.
The temperatures at which the light scattering of
 .  .Pro –Glu NHC H decreases in pure HBS and3 16 33 2
in 30% MeOH, in general, correlate with the Tm
 .values measured by DSC Table 2 . According to the
 .DSC data, the influence of 30% MeOH on Pro –3
 .Glu NHC H phase transition is consistent with16 33 2
that of DC PC which shows moderate T decrease8,9 m
w xat low concentrations of short chain alcohols 23,30 .
3.4. Stability of HARMs
For some potential pharmaceutical applications of
lipopeptide HARMs, it would be advantageous if the
microstructures do not change morphology on inter-
action with biological fluids or cell membranes,
whether through loss of monomeric surfactants or
other mechanisms. One lipopeptide was chosen to
test the survival of HARMs in simulated biological
fluids. Fig. 8 shows that during incubation for 45 h at
 .  .408C, HARMs made of Pro –Glu NHC H do3 16 33 2
 .not change significantly in HBS used as a control ,
( )K.C. Lee et al.rBiochimica et Biophysica Acta 1371 1998 168–184 183
 .  .  .  .  .  .Fig. 8. Pro –Glu NHC H HARMs before Ia–Ic and after IIa–IIc 45 h incubation at 408C in HBS a , FCS b , and DOPC3 16 33 2
 .liposomal suspension c .
 .in fetal calf serum modeling extracellular fluids , or
in the presence of an excess of DOPC liposomes
 .used to model cell membranes at a 1:30 molar
lipopeptiderDOPC ratio. Aside from some aggrega-
tion of HARMs, these treatment did not detectably
alter HARM morphology. This demonstrates that the
presence of lipid membranes or components of blood
plasma alone at physiological temperature is not im-
mediately detrimental to this type of microstructure.
Upon injection into mammals, the morphology of
these HARMs are not expected to change dramati-
cally, so they should provide a suitable matrix for
extended continuous release in a manner that is char-
acteristic of their shape.
( )K.C. Lee et al.rBiochimica et Biophysica Acta 1371 1998 168–184184
4. Conclusions
Using 10 different amphiphiles, we have shown
that lipidation of peptides using glutamic acid dialky-
lamides is a simple, and perhaps universal method to
cause short peptides to self-assemble into HARMs.
Despite significant structural differences between the
lipopeptides studied and tubule-forming diacetylenic
phospholipids, techniques developed for formation of
DC PC HARMs were readily adapted for use with8,9
the lipopeptides studied, although, in some cases,
fabrication of uniform HARMs will require optimiza-
tion of conditions including buffer composition and
cooling rate. Fast, simple, and quantitative formation
of uniform HARMs was possible with most com-
pounds described. This provides a basis for further
investigation of physico–chemical properties of these
particles to determine their molecular conformation
and their pharmacological potential.
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